Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreMaintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial
Type de publicationJournal Article
Year of Publication2020
AuteursA. Martin G, Tazi Y., Heitz F., Montane L., Gargiulo P., Berger R., Yonemori K., Vergote I., Bologna A., Maenpaa J., Costan C., Canzler U., Zamagni C., Guerra-Alia E.M, Levache C.B, Marme F., Kalbacher E., De Gregorio N., Dohollou N., Ray-Coquard I.L
JournalANNALS OF ONCOLOGY
Volume31
PaginationS1163-S1164
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2020.08.2263